British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022
- PMID: 36763868
- DOI: 10.1093/bjd/ljac042
British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022
Conflict of interest statement
Conflicts of interest: The following interests were declared over the duration of the guideline development. A.J.B.: (1) invited speaker at educational events – Almirall, LEO Pharma (nonspecific); (2) part owner of the trademark Altruist – a urea-containing cream (specific). C.B.: speaker at educational courses on PDT organized by Galderma (specific). C.A.M.: (1) invited speaker – Biofrontera (specific); (2) travel expenses – Galderma (specific); (3) grant/research support – Biofrontera (specific). Z.-U.H.: grant/research support – Meda Pharmaceuticals, NIHR Clinical Research Network: Cancer (nonspecific). A.S., S.T.C., J.M., A.S., M.H., Z.M.K., M.F.M.M. and L.S.E. declare they have no conflicts of interest.
Comment in
-
Update on the management of Bowen disease with a focus on patients' needs.Br J Dermatol. 2023 Feb 10;188(2):166. doi: 10.1093/bjd/ljac087. Br J Dermatol. 2023. PMID: 36637108 No abstract available.
-
Guidelines from the British Association of Dermatologists for the management of people with squamous cell carcinoma in situ (Bowen disease).Br J Dermatol. 2023 Feb 10;188(2):e13. doi: 10.1093/bjd/ljac160. Br J Dermatol. 2023. PMID: 36763891 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical